Myasthenia Gravis Clinical Trial
Official title:
Sensitivity of Repetitive Nerve Stimulation Performed in the Evening vs in the Morning and With Single vs Repeated Effort in Myasthenia Gravis
Myasthenia gravis (MG) is the autoimmune disorder affecting the neuromuscular junction, characterized by fatigue, which increases gradually through the day. The repetitive nerve stimulation (RNS) remains the key diagnostic test in MG, however its sensitivity, especially in ocular form of MG is not satisfactory. In this study, investigators want to assess the impact of the time of the day on the sensitivity of the RNS. We hypothesize the RNS performed in the evening may be more sensitive than in the morning.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | September 1, 2024 |
Est. primary completion date | May 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Patients with suspected or diagnosed myasthenia gravis (ocular and generalized form) - Patients with performed or planned determination of anti-AChrR and anti-MUSK antibodies. - Disease severity of at least 1 in the classification of the severity of myasthenia gravis according to the recommendations of the Myasthenia Gravis Foundation of America Exclusion Criteria: - respiratory failure - severe bulbar symptoms - pharmacotherapy with substances that may worsen neuromuscular transmission disorders - current infection - coexisting diseases of the peripheral nervous system which may affect the result of the fatigue test, e.g. polyneuropathy or myopathy - cognitive and behavioral disorders that may negatively affect patient's adherence to study protocol - Medication with steroids due to myasthenia - Severity of myasthenia that makes the discontinuation of acetylcholinesterase inhibitors unsafe. |
Country | Name | City | State |
---|---|---|---|
Poland | Jagiellonian University Medical College, Department of Neurology | Kraków | Lesser Poland |
Lead Sponsor | Collaborator |
---|---|
Jagiellonian University |
Poland,
Bou Ali H, Salort-Campana E, Grapperon AM, Gallard J, Franques J, Sevy A, Delmont E, Verschueren A, Pouget J, Attarian S. New strategy for improving the diagnostic sensitivity of repetitive nerve stimulation in myasthenia gravis. Muscle Nerve. 2017 Apr;55 — View Citation
Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ne — View Citation
Witoonpanich R, Dejthevaporn C, Sriphrapradang A, Pulkes T. Electrophysiological and immunological study in myasthenia gravis: diagnostic sensitivity and correlation. Clin Neurophysiol. 2011 Sep;122(9):1873-7. doi: 10.1016/j.clinph.2011.02.026. Epub 2011 — View Citation
Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999 Apr 22;52(7):1487-9. doi: 10.1212/wnl.52.7.1487. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Difference in the highest decrement between investigation of nasalis during morning and evening RNS | Difference in the highest decrement between investigation of nasalis during morning (at 8:30 or 8:50 a.m.) RNS with single one-minute voluntary effort and RNS at 2:30 p.m. | Through study completion, an average of 1 year. | |
Primary | Difference in the highest decrement between investigation of trapezius during morning and evening RNS | Difference in the highest decrement between investigation of trapezius during morning (at 8:30 or 8:50 a.m.) RNS with single one-minute voluntary effort and RNS at 2:30 p.m. | Through study completion, an average of 1 year. | |
Primary | Difference in the highest decrement between investigation of nasalis during morning RNS with single and with two voluntary efforts | Difference in the highest decrement between investigation of nasalis during morning (at 8:30 or 8:50 a.m.) RNS with single one-minute voluntary effort and RNS with two one-minute voluntary efforts. | Through study completion, an average of 1 year. | |
Primary | Difference in the highest decrement between investigation of trapezius during morning RNS with single and with two voluntary efforts | Difference in the highest decrement between investigation of trapezius during morning (at 8:30 or 8:50 a.m.) RNS with single one-minute voluntary effort and RNS with two one-minute voluntary efforts. | Through study completion, an average of 1 year. | |
Secondary | Difference in the percentage of abnormal RNS results between RNS performed in the morning and in the evening | Difference in the percentage of abnormal RNS results between RNS with single one-minute voluntary effort performed in the morning (at 8:30 or 8:50 a.m.) and RNS performed at 2:30 p.m. | Through study completion, an average of 1 year. | |
Secondary | Difference in the percentage of abnormal RNS results between RNS performed in the morning with single and with two voluntary efforts | Difference in the percentage of abnormal RNS results between RNS with single one-minute voluntary effort performed at 8:30 or 8:50 a.m. and RNS with two one-minute voluntary efforts. | Through study completion, an average of 1 year. | |
Secondary | Correlation between the highest decrement during morning RNS with single one-minute voluntary effort and the MG-ADL score | Correlation between the highest decrement during RNS with single one-minute voluntary effort, performed at 8:30 or 8:50 AM and the MG-ADL score | Through study completion, an average of 1 year. | |
Secondary | Correlation between the highest decrement during RNS with two one-minute voluntary efforts and the MG-ADL score | Correlation between the highest decrement during RNS with two one-minute voluntary efforts, and the MG-ADL score | Through study completion, an average of 1 year. | |
Secondary | Correlation between the highest decrement during evening RNS and the MG-ADL score | Correlation between the highest decrement during RNS performed at 2:30 p.m. and the MG-ADL score | Through study completion, an average of 1 year. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05039190 -
Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients
|
Phase 3 | |
Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
Completed |
NCT01727193 -
The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy
|
Phase 3 | |
Completed |
NCT00285350 -
Mycophenolate Mofetil in Myasthenia Gravis
|
Phase 3 | |
Recruiting |
NCT05890833 -
The Risk of Falls Index for Patients With Neuromuscular Disorders
|
||
Completed |
NCT05694234 -
Influences of Sugammadex on Postoperative Progress in Patients With Myasthenia Gravis Undergoing Video-assisted Thoracoscopic Thymectomy: Retrospective Study
|
||
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Not yet recruiting |
NCT04965987 -
Oxaloacetate in Myasthenia Gravis
|
Phase 1 | |
Not yet recruiting |
NCT05095103 -
Immune Profiles in Myasthenia Gravis
|
||
Terminated |
NCT02102594 -
Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)
|
Phase 2 | |
Completed |
NCT02066519 -
Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis
|
N/A | |
Completed |
NCT02774239 -
A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)
|
Phase 3 | |
Completed |
NCT02118805 -
Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
|
||
Terminated |
NCT01828294 -
Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis
|
Phase 1 | |
Terminated |
NCT00727194 -
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
|
Phase 2 | |
Completed |
NCT04590716 -
Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
|
||
Recruiting |
NCT04837625 -
Study of Myasthenic Crisis in China
|
||
Not yet recruiting |
NCT01469858 -
Perception and Multisensory Integration in Neurological Patients Using fMRI
|
N/A | |
Completed |
NCT05408702 -
Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
|
||
Completed |
NCT03205306 -
Myasthenia Gravis and Psyche
|